Stelo by Dexcom is the first over-the-counter continuous glucose monitor (CGM) in the U.S. Though specifically designed for people with prediabetes or type 2 diabetes who don’t use insulin, anyone 18 ...
StockStory.org on MSN
Unpacking Q4 earnings: ResMed (NYSE:RMD) in the context of other patient monitoring stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
StockStory.org on MSN
Q4 patient monitoring earnings review: First prize goes to iRhythm (NASDAQ:IRTC)
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...
According to Dexcom, the company’s new data emphasises the case to expand its CGM for people with all types of diabetes. Credit: Michael Vi / Shutterstock.com Dexcom is poised to share new data on the ...
BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for ...
New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy 1, reinforcing the need to broaden ...
Dexcom ( (DXCM)) just unveiled an update. On February 26, 2026, Dexcom’s board expanded to twelve members and appointed Rick Osterloh, Google’s Senior Vice President for Platforms & Devices, as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results